NervGen Pharma
NervGen Pharma Corp. · NGEN (TSXV) · Vancouver, BC · Pharmaceuticals
Latest R&D (CAD)
$13.9M
Period ended 2025-12-31
Revenue (CAD)
—
Intensity —
R&D by fiscal period
2025
$13.9M
2024
$15.8M
2023
$8.0M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $13,907,206 | — | $13,907,206 CAD | Annual financial statements | Annual report |
| 2024-12-31 | $15,811,020 | — | $15,811,020 CAD | Annual financial statements | Annual report |
| 2023-12-31 | $8,046,313 | — | $8,046,313 CAD | Annual financial statements | Annual report |